Ra Medical Q1 net loss $66.4M, goodwill impaired $56.1M; revenue $85K

Catheter Precision, Inc.

Revenue of $85K vs $9K YoY; net loss $66.4M includes $56.1M goodwill impairment.
Cash used in operations $12.1M, incl. $5M DOJ settlement payment; cash $12.2M at Mar 31.
Acquisition of Catheter Precision closed Jan 2023; $8M financing obtained in March.
CEO Will McGuire resigned; David Jenkins named Interim CEO; Steve Passey appointed CFO.
VIVO system launch underway with five direct sales reps; LockeT closure device introduced.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Catheter Precision, Inc. reported the three months ended March 31, 2023 results: revenue $85 thousand, net income net loss was $66.4 million.

Period: the three months ended March 31, 2023
Revenue: $85 thousand
Net income: net loss was $66.4 million
Result: reported results

Exact text from the filing

Passey. · Announced the resignation of its CEO, and appointment of its new Interim CEO, David Jenkins, as of April 28, 2023. · Revenues for the quarter ended March 31, 2023 were $85 thousand, net loss was $66.4 million and cash used by operations was $12.1 million, which includes a $5.0 million cash payment associated with a legacy settlement. Accounting for the

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Catheter Precision, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-007595

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.